Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
InterShunt Technologies
Fridley, Minnesota, United Statesintershunt.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
InterShunt Technologies is developing the Percutaneous Atrial Shunt Catheter (PAS-C) system, a proprietary transcatheter device that creates a controlled interatrial shunt without leaving an implant or using energy. The approach has shown promising safety and efficacy in pre-clinical studies and early human trials for reducing left atrial pressure in heart failure patients[1][2].
- Therapeutic areas
- Cardiovascular
- Modalities
- DeviceCatheter-based therapyMechanical system (no implant, no energy)
- Industry
- Therapeutic Medical Devices
02
Partnerships
Solas BioVentures (investor/partner)Arsenal Capital Management (investor/partner)
Beyond the preview
Go deeper on InterShunt Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InterShunt Technologies.